← 홈

건선 · IL-17A

17개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 17개
AntibodySHOTFDACuratedFDABiologicNovartisApproved

secukinumab (Cosentyx)

Psoriasis, psoriatic arthritis, ankylosing spondylitis · IL-17A

#IL-17A#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 78.1%임상시험 153상태 APPROVED
AntibodyBNovartisApproved

AIN457 (Secukinumab, Secukinumab (AIN457))

Psoriatic Arthritis · Moderate to Severe Plaque-type Psoriasis

#ModeratetoSeverePlaque-typePsori#Antibody#Approved#인기#항체+4
효능 ORR 53%임상시험 98상태 ACTIVE
AntibodyBNovartisPhase 3

secukinumab (AIN457, AIN457 (secukinumab))

Asthma · Psoriatic Arthritis

#PsoriaticArthritis#Antibody#Phase3#인기#항체+4
효능 ORR 53%임상시험 95상태 ACTIVE
AntibodyEli Lilly and CompanyApproved

Ixekizumab (Ixekizumab)

Psoriasis; Atopic Dermatitis · Psoriatic Arthritis

#PsoriaticArthritis#Antibody#Approved#인기#항체+5
임상시험 53상태 RECRUITING
AntibodystaleNovartisPhase 3

Investigational Arm - secukinumab (Investigational Arm - secukinumab)

Plaque Psoriasis; Non-alcoholic Fatty Liver Disease · Plaque Psoriasis

#PlaquePsoriasis#Antibody#Phase3#항체#면역항체+3
임상시험 5상태 DISCONTINUED
AntibodystaleNovartisPhase 3

Experimental : Secukinumab low dose (Experimental : Secukinumab low dose)

Chronic Severe Plaque-type Psoriasis · Chronic Severe Plaque-type Psoriasis

#ChronicSeverePlaque-typePsoriasi#Antibody#Phase3#항체#면역항체+2
임상시험 2상태 ACTIVE
AntibodystaleNovartisPhase 3

Experimental: Secukinumab high dose (Experimental: Secukinumab high dose)

Chronic Severe Plaque-type Psoriasis · Chronic Severe Plaque-type Psoriasis

#ChronicSeverePlaque-typePsoriasi#Antibody#Phase3#항체#면역항체+2
임상시험 2상태 ACTIVE
AntibodystaleNovartis PharmaceuticalsPreclinical

Secikinumab (Secikinumab)

Axial Spondylarthritis (axSpA); Secukinumab · Psoriasis

#Psoriasis#Antibody#Preclinical#항체#면역항체+4
임상시험 2상태 ACTIVE
AntibodystaleNovartisPhase 3

"Secukinumab" "Cosentyx TM" ("Secukinumab" "Cosentyx TM")

Psoriasis · Psoriasis

#Psoriasis#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleNovartisPhase 1

Cosentyx（Secukinumab ） (Cosentyx（Secukinumab ）)

Psoriasis · Psoriasis

#Psoriasis#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleUniversity Hospital, GhentApproved

Proactive TDM-based dosing of ixekizumab (Proactive TDM-based dosing of ixekizumab)

Psoriasis Vulgaris · Psoriasis Vulgaris

#PsoriasisVulgaris#Antibody#Approved#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleUniversity Hospital, GhentApproved

Proactive TDM-based dosing of secukinumab (Proactive TDM-based dosing of secukinumab)

Psoriasis Vulgaris · Psoriasis Vulgaris

#PsoriasisVulgaris#Antibody#Approved#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleNovartisApproved

Secukinumab Auto-Injector (Secukinumab Auto-Injector)

Psoriasis · Psoriasis

#Psoriasis#Antibody#Approved#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleNovartisPhase 1

Secukinumab Auto-Injector [Cosentyx] (Secukinumab Auto-Injector [Cosentyx])

Psoriasis · Psoriasis

#Psoriasis#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleAbbViePreclinical

adalimumab (Humira, adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate)

Immunoclassification; Psoriasis · Immunoclassification

#Immunoclassification#Antibody#Preclinical#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleNovartisPhase 3

secukinumab high dose (secukinumab high dose)

Moderate to Severe Chronic Plaque-type Psoriasis · Moderate to Severe Chronic Plaque-type P

#ModeratetoSevereChronicPlaque-ty#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleNovartisPhase 3

secukinumab low dose (secukinumab low dose)

Moderate to Severe Chronic Plaque-type Psoriasis · Moderate to Severe Chronic Plaque-type P

#ModeratetoSevereChronicPlaque-ty#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE